This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article, Sangamo Therapeutics’ Chief Scientific Officer, Jason Fortenot, explains why CAR Tregs may become transformational therapeutics for immune-mediated diseases, highlighting the challenges his company has overcome to get the first ever engineered Treg therapy into clinical trials. How do CAR Tregs differ from T cells?
Brand Authority: By appearing at the top of search engine results, pharmaceutical companies increase brand credibility among HCPs. This includes: Disclosing risks and sideeffects in ad copy when mentioning drug benefits. Avoiding misleading claims that exaggerate efficacy or safety.
the promise of leveraging oncolytic viruses stands out because of their excellent safety profile, minimal predicted sideeffects and potent ability to kill cancer cells while leaving healthy cells unscathed2. While oncolytic viruses do occur in nature, those used as therapies are typically engineered in a lab.
Health-related quality of life scores were also higher in patients treated with TIL than Yervoy, said Haanen, and no new safety issues were found with the cell therapy, which can be hard to tolerate with grade 3 or higher adverse events occurring in all patients treated.
The answer is simple search engines and social platforms are where patients and HCPs find information. A single misstepsuch as targeting the wrong audience or omitting safety disclaimers can lead to regulatory violations and ad disapprovals. With Google processing over 8.5 The challenge?
It was engineered using a unique, proprietary glycoPEGylated technology to prolong the biological activity (half-life), while maintaining the efficacy of native FGF21, a metabolic hormone. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) sideeffects.
This blog post could provide information about the drug’s potential benefits, its sideeffects, and how it compares to other drugs on the market. For example, a pharmaceutical company could create a blog post about a new drug that it is developing.
Using this flexible platform, Ambrx is developing engineered precision biologics with site-specific, homogenous, and stable conjugation to overcome limitations of traditional ADC technologies. We reverse-engineered how T cells become activated during an immune response by mimicking the presentation of natural immune “cues.”
1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of sideeffects. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.
While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower sideeffects and enhanced treatment convenience.
BTKis, oral drugs given as continuous monotherapy, have revolutionised the treatment of CLL, with the first generation BTKi ibrutinib receiving European Medicines Agency (EMA) approval in 2014; however, side-effects (such as cardiovascular toxicities 2 ) have limited its suitability. for all-comers; HR=0.52
One of the primary objectives of pharma marketing is to communicate the benefits and safety profiles of medications to healthcare providers and patients. Digital marketing strategies, including search engine optimization (SEO), content marketing, and online advertising, have become integral components of pharmaceutical marketing campaigns.
A strong brand message conveys the unique value proposition of the pharmaceutical product, highlighting its benefits, efficacy, and safety. An effective brand message not only differentiates the product from competitors but also establishes credibility and trust with the target audience.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content